Redeye updates its estimates and valuation following MedCap’s Q3 2025 report. Both sales and adjusted EBITA beat our forecasts. Encouragingly, organic growth of c9% y/y represented a continued sequential improvement. M&A activity has ramped year-to-date. We believe soft organic growth comparables and substantial financial M&A capacity bode well for coming quarters, though the share’s price seemingly reflects this potential.
LÄS MER
